Anteris Technologies Global CORP

Anteris Technologies Global Corp. announced that the Federal Court of Australia granted its application to rectify an administrative oversight concerning a late cleansing notice, leading to the lifting of a trading halt.

Anteris Technologies Global Corp. has requested a trading halt on its securities pending consideration of an inadvertent non-lodgement of cleansing notices for CHESS Depositary Interests.

Anteris Technologies Global Corp. has entered into a sales agreement with TD Securities (USA) LLC to offer and sell up to $250 million of its common stock through an at-the-market (ATM) program.

Anteris Technologies Global Corp. has elected to discontinue development contributions under a material agreement with v2vmedtech, inc., triggering a $400,000 break fee and potential equity adjustments.

Anteris Technologies Global Corp. has entered into a long-term lease agreement for a 181,436 square foot facility in Brooklyn Park, Minnesota.

Anteris Technologies Global Corp. reported a significant increase in net loss for 2025, alongside a 29% revenue decline, but secured $320 million in early 2026 capital raises and advanced its pivotal DurAVR THV trial.

Anteris Technologies Global Corp. reported increased losses in Q3 2025 as R&D expenses surged for its DurAVR THV System, while successfully raising $25.2 million post-period to fund ongoing operations and clinical trials.

Anteris Technologies Global Corp. reports increased losses in Q2 2025 as it ramps up manufacturing and clinical infrastructure for the PARADIGM Trial.

Anteris Technologies Global Corp. reports a net loss of $21.9 million for the first quarter of 2025, driven by increased R&D spending as it prepares for the PARADIGM Trial.

Anteris Technologies Global Corp. reported significant R&D investments and net losses in 2025, while successfully initiating its pivotal PARADIGM Trial and securing substantial capital raises in late 2025 and early 2026.

Anteris Technologies files an amendment to its 2024 annual report to include previously omitted information regarding directors, executive compensation, and related corporate governance matters.

Anteris Technologies Global Corp.'s 10-K filing highlights its ongoing development of the DurAVR THV system, clinical trial progress, and financial position as a development-stage company.

L1 Capital Pty Ltd reported changes in beneficial ownership of Anteris Technologies Global Corp. common stock on July 31, 2026.

L1 Capital Pty Ltd reported changes in beneficial ownership of Anteris Technologies Global Corp. common stock on July 29, 2026.

L1 Capital Pty Ltd reported changes in beneficial ownership of Anteris Technologies Global Corp. common stock on July 27, 2026.

L1 Capital Pty Ltd reported changes in beneficial ownership of Anteris Technologies Global Corp. common stock on October 28, 2025.

L1 Capital Pty Ltd reported changes in beneficial ownership of Anteris Technologies Global Corp. common stock on July 24, 2026.

Director Gregory S. Moss converted 17,580 restricted stock units into common stock following the first vesting installment of a 2025 equity grant.

Anteris Technologies Global Corp. announces its 2025 Annual Meeting of Stockholders to address director elections, auditor ratification, and significant RSU grants for executives and non-employee directors.

Anteris Technologies Global Corp. adjourned its Special Meeting of Stockholders to September 29, 2025, after failing to achieve a quorum for key proposals, including an ASX waiver for issuing new securities.

Anteris Technologies Global Corp. has postponed its Special Meeting of Stockholders by one week to allow for broader participation and additional voting time.

Anteris Technologies Global Corp. has postponed its Special Meeting of Stockholders to September 11, 2025, to allow for broader stockholder participation.

Anteris Technologies Global Corp. is seeking stockholder approval for an ASX waiver to issue new securities without further shareholder consent, aiming for greater capital raising flexibility.

Anteris Technologies Global Corp. filed an S-1 registration statement for the resale of up to 9.1 million common shares by selling stockholders, following a recent private placement and warrant issuance.

Anteris Technologies Global Corp., a structural heart company, has filed for an initial public offering (IPO) in the U.S. to support the development and commercialization of its innovative DurAVR transcatheter heart valve system.

Anteris Technologies Global Corp., a structural heart company, has filed for an initial public offering (IPO) in the U.S. to support the development and commercialization of its innovative DurAVR transcatheter heart valve system.

Medtronic plc, through its affiliate Covidien Group S.a.r.l., has acquired a 16.2% stake in Anteris Technologies Global Corp. for $90 million, establishing a strategic partnership.

Nantahala Capital Management, LLC and its principals have reported a 6.28% beneficial ownership stake in Anteris Technologies Global Corp.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 7.52% beneficial ownership in Anteris Technologies Global Corp. as of December 31, 2025.

L1 Capital Pty Ltd has significantly increased its beneficial ownership in Anteris Technologies Global Corp. to 13.60% of common stock.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 4.9% beneficial ownership stake in Anteris Technologies Global Corp. as of December 31, 2025.

Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, reported a 5.32% beneficial ownership stake in Anteris Technologies Global Corp. as of September 30, 2025.

L1 Capital Pty Ltd has increased its beneficial ownership in Anteris Technologies Global Corp. to 19.9% of common stock, holding over 8.2 million shares.